WuXi Biologics receives two awards at 2026 HERA

CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation

Agilent acquires Proscia for USD240m

BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma

Sectra wins seven-year radiology reporting contract with Mount Sinai Health System

Pentixapharm advances preparationsfor Phase 3 PANDA study

ABIONYX Pharma partners with Lille University Hospital to explore CER-001 for severe burn patients

Samsung Biologics awarded 'Negligible Risk' rating in Sustainalytics ESG assessment

CStone and Kimia Therapeutics collaborate to advance oncology drug candidate

Moberg Pharma secures US patent for MOB-015 dosing regimen

Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention

Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia

Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial

Ultima Genomics UG200 Sequencing Platform selected for SG-INSIGHT study

Fresenius and WuXi Biologics agree biosimilars development partnership